SRPT as of Nov 2 · 16:50 ET

SRPTNasdaqPharmaceutical Preparations

Sarepta Therapeutics, Inc. · Brief

Next report

Today

Nov 2 · after closeest.Q3 FY26

Earnings

Expected move

Inputs

±9.8%implied · straddle

16.7920.45

spot 18.62exp Nov 6ATM strike 18.5ATM straddle 2.15IV 105%

Oct 30 close

Expected move

Inputs

Implied vs realized

8 reportsHistory

—≥ implied

Jan 13 '25—▼−5.10%—

Feb 26 '25—▼−3.56%—

Jul 16 '25—▲+19.53%—

Q3 FY25—▼−33.74%—

Jan 12 '26—▼−11.29%—

Q1 FY26—▼−8.01%—

May 6 '26—▼−9.68%—

Q2 FY26±9.2%▲+5.34%×0.58

quarterimplied−35%0+35%realized×

Q2 FY26±9.2%▲+5.34%×0.58

May '26—▼−9.68%—

Q1 FY26—▼−8.01%—

Jan '26—▼−11.29%—

Q3 FY25—▼−33.74%—

Jul '25—▲+19.53%—

2 older reports

Feb '25—▼−3.56%—

Jan '25—▼−5.10%—

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 2 report · est.

Bull2

9disclosed supplier and customer ties in SEC filingsSEC filings

327managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2 of 3

5tracked funds holding SRPTN-PORT · Aug 31 '26

0.75%State Street SPDR S and P Biotech ETF assets as largest fund weightN-PORT · Jun 30 '26

AI captions · Sep 28 '26once per report · top 2 per case

Linked exposure

SRPT report session

Suppliers 1

ARWRArrowhead×0.30

× = co-movement · max 501dSource: SEC filings · market data

Latest changes

30 daysAll changes

Oct 19impliedImplied move: ±11.6% into Nov 2 earnings (Oct 19 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.